Life Sciences

  • May 06, 2026

    'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told

    Johnson & Johnson and a consultant it hired in the 1970s altered the conclusions of tests that found alarming levels of asbestos in the company's talc products before giving different results to the U.S. Food and Drug Administration, a former FDA commissioner told a Los Angeles jury Wednesday.

  • May 06, 2026

    Trulieve Twists Patent Pleading Standard, Cannabis Co. Says

    A cannabis patent holder urged a Florida federal court to reject Trulieve Inc.'s effort to toss an infringement complaint, arguing that proof of its claims isn't needed when initially filing a lawsuit. 

  • May 06, 2026

    Judge Questions OMB Justification For Voiding Grants

    A Massachusetts federal judge on Wednesday pushed back on arguments by the Trump administration that federal agency grants are subject to termination at any time based solely on a change in priorities — a situation, she suggested, that would essentially render any contracts with the government "illusory."

  • May 06, 2026

    Judge Won't Certify Minn. Fraud Question In Cancer Drug MDL

    A New Jersey federal judge won't ask the Supreme Court of Minnesota to weigh in on whether an insurer can pursue claims using a state law typically reserved for the attorney general in litigation alleging drugmaker Celgene used charitable donations to manipulate the price of cancer drugs.

  • May 06, 2026

    Calif. Justices Seem Divided On Gilead HIV Negligence Claim

    The California Supreme Court appeared split Wednesday over whether Gilead should face a negligence claim for allegedly withholding a safer HIV drug from the market to maximize profits from an older drug with more harmful side effects. 

  • May 06, 2026

    9th Circ. Won't Revive Hospital Workers' Vaccine Bias Suit

    The Ninth Circuit refused Wednesday to reopen a religious bias lawsuit accusing a Washington hospital of unlawfully denying employees' requests to avoid a COVID-19 vaccination mandate, finding that the medical center demonstrated that exemptions would've been too burdensome under a 2023 U.S. Supreme Court decision.

  • May 06, 2026

    Alto Says Investors Use Hindsight In Suit Over Drug Trial

    Alto Neuroscience has urged a California federal judge to toss an investor suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, saying the suit is a "classic case of trying to plead fraud by hindsight."

  • May 06, 2026

    CellCentric Closes Latest Funding Round With $220M In Tow

    Clinical-stage biotechnology company CellCentric on Wednesday revealed that it closed its oversubscribed Series D financing round after securing $220 million from investors.

  • May 05, 2026

    DC Circ. Judge Jabs Pharma Atty For 10 Minutes In Price Fight

    The first D.C. Circuit showdown in widespread drug pricing litigation Tuesday appeared unlikely to deliver a badly needed win to the pharmaceutical industry, as a top manufacturer's attorney faced a cool reception generally and an extended barrage of skepticism from one judge.

  • May 05, 2026

    Ex-FDA Chief Testifies 100s Of J&J Docs Tie Asbestos To Talc

    A former U.S. Food and Drug Administration commissioner on Tuesday testified in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused deadly ovarian cancer in three women, saying hundreds of internal company documents reveal the company knew for decades that its talc contained asbestos.

  • May 05, 2026

    Cannabis Giants Sued Over Mental Health Marketing

    Recreational cannabis users hit some of the industry's largest companies — Cresco Labs, Green Thumb Industries, Verano Holdings and Curaleaf — with two sprawling lawsuits alleging the businesses overcharged for products deceptively marketed as safe and effective treatments for mental health disorders.

  • May 05, 2026

    Sanofi Unit Gets Backup In Fed. Circ. Double Patenting Appeal

    Canon, Sonos and several other tech and biopharma companies have thrown their weight behind a Sanofi subsidiary's appeal challenging how the Patent Trial and Appeal Board handles obviousness-type double patenting.

  • May 05, 2026

    ERISA Recap: 5 Litigation Developments From April

    The U.S. Supreme Court turned down a bakery company's bid for review of a union multiemployer pension withdrawal bill, the Fourth Circuit held a bonus plan was exempt from federal benefits law, and the Sixth Circuit ruled federal law preempted Arkansas pharmacy benefit manager laws and regulations. Here's more on those and two other major decisions from April that benefits attorneys may want to know.

  • May 05, 2026

    Apple Urges Full Fed. Circ. To Undo Original Watch Import Ban

    A Federal Circuit panel erred when finding the U.S. International Trade Commission properly banned imports of Apple Watches with blood oxygen-monitoring features, the tech giant behind the devices said in a plea for rehearing by the full court.

  • May 05, 2026

    $100M AI Investment Suit Must Be Arbitrated, Financier Says

    A California financier Tuesday denied allegations in a $100 million fraud lawsuit over a "sham" loan transaction aimed at funding an investment into an artificial intelligence company, adding that the dispute belongs in arbitration in the Bahamas.

  • May 05, 2026

    Mylan Strikes $4.5M Deal With Maryland Over EpiPen Pricing

    Mylan Pharmaceuticals will pay $4.5 million to resolve allegations by the state of Maryland that Mylan acted anticompetitively when it ratcheted up costs of its portable auto-injectable EpiPen device that's used during life-threatening allergic reaction episodes, according to a recent announcement.

  • May 05, 2026

    4th Circ. Backs Raytheon In Ex-Workers' Vaccine Bias Case

    The Fourth Circuit upheld RTX Corp.'s defeat of a lawsuit claiming it forced out employees who received religious exemptions to its COVID-19 vaccine policy, ruling Tuesday that the ex-workers behind the suit filed their claims too late.

  • May 05, 2026

    Amylyx Investors To Get $6.5M In ALS Drug Settlement

    Amylyx Pharmaceuticals and a class of shareholders are seeking judicial approval for a $6.5 million settlement to resolve allegations that the drugmaker overstated the commercial potential of a treatment for amyotrophic lateral sclerosis, or ALS, that was ultimately shelved.

  • May 05, 2026

    CooperSurgical Strikes Deal To End Embryo Loss Class Suit

    Connecticut-based fertility products manufacturer CooperSurgical Inc. has reached a settlement with a proposed class of in vitro fertilization patients and their partners, who claimed the company's defective product caused the loss of their embryos.

  • May 05, 2026

    Sandoz, Novartis Must Face Generics Claims From GM, Others

    A Pennsylvania federal judge largely refused to let dozens of generic-drug makers duck stand-alone price-fixing and market allocation antitrust claims from major employers like General Motors, American Airlines and Lowe's, nixing allegations against a small handful while importantly preserving them against Novartis and its former Sandoz subsidiary.

  • May 05, 2026

    Deutsche, Pathward Want Fintech Blacklist Suit Tossed

    Deutsche Bank AG and Pathward NA urged a New York federal court to dismiss a suit accusing them of improperly blacklisting a barter-based payment platform that the banks found was "transaction laundering" for companies selling gray-market pharmaceuticals, arguing that the suit's jurisdiction assertions are fatal to the claims.

  • May 05, 2026

    Travelers Unit Says No Coverage In Cannabis Explosion Suits

    A Travelers Property Casualty Corp. unit is suing two of its insureds in California federal court, seeking a declaration that its insurance policies don't cover defense and indemnity of suits over a deadly explosion allegedly caused by an illegal cannabis operation.

  • May 04, 2026

    'They Knew It': J&J Accused Of Hiding Talc Risk At LA Trial

    Johnson & Johnson knew for decades that its baby powder contained asbestos, even as it advertised the product as safe and "pure," attorneys for the families of three women who died of ovarian cancer told a California jury Monday during opening statements in a bellwether trial.

  • May 04, 2026

    Biotech Overhyping Obesity Drug Hurt Investors, Suit Says

    Current and former executives of drugmaker Skye Bioscience Inc. breached their fiduciary duties by overstating an obesity drug's clinical prospects and precipitating a trading price decline when the company revealed disappointing study results, an investor has alleged.

  • May 04, 2026

    Judge Shuts Down Invalidity Theory In Abiomed IP Case

    A Massachusetts federal judge has foreclosed one of Abiomed's invalidity defenses in a case brought by rival medical technology firm Maquet over alleged infringement of a patent covering blood pump technology.

Expert Analysis

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

  • 2 Strands Of Patent Law In High Court's 'Skinny Label' Case

    Author Photo

    Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.

  • Why MDLs Slow Down — And How To Speed Them Up

    Author Photo

    Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.

  • A Check-Up On HHS' Push To Implement AI Infrastructure

    Author Photo

    The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.

  • What A Court Doc Audit Reveals About Erroneous Filings

    Author Photo

    My audit of 1,522 court documents from last month found that over 95% contained at least one verifiable error, with fewer than 1% showing clear indicators of artificial intelligence use — highlighting above all else that lawyers may want to focus most on strengthening their review processes, says Elliott Ash at ETH Zurich.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q1

    Author Photo

    Michigan's financial services sector saw several significant developments in 2026's first quarter, including the state Department of Insurance and Financial Services' issuance of a bulletin on the use of artificial intelligence and the Michigan House's introduction of a bill based on the Model Money Transmission Modernization Act, say attorneys at Dykema.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.